BioNTech to Present New Clinical and Preclinical Data Across Multiple Immuno-Oncology Programs at 36th SITC Annual Meeting
01 Oktober 2021 - 2:12PM
BioNTech to Present New Clinical and Preclinical Data Across
Multiple Immuno-Oncology Programs at 36th SITC Annual Meeting
MAINZ, Germany, October 1, 2021 (GLOBE
NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the
Company”), a next generation immunotherapy company pioneering novel
therapies for cancer and infectious diseases, today announced that
new clinical and preclinical data will be presented in six posters
and one presentation at the 36th Annual Meeting of the Society for
Immunotherapy of Cancer (SITC), being held both in person and
virtually from November 10 - 14, 2021. The presentations will
include new data from multiple programs across various drug classes
along with first-in-human data for three programs. This is the
largest data collection the company will present at a scientific
meeting, showcasing BioNTech’s diversified oncology pipeline.“The
data we will be presenting at SITC 2021 is indicative of our
continued pursuit of pathbreaking science and the development of
our platform technologies that tailor anti-cancer therapies to
individual patient needs,” said Özlem Türeci, M.D., Co-Founder
and Chief Medical Officer at BioNTech. “We are encouraged by
the considerable progress within our oncology portfolio seeing
multiple programs now coming to fruition. They represent critical
steps for us towards bringing cancer immunotherapy into the next
generation and we are looking forward to sharing the data with the
scientific community at a key conference.” Presentation
Details:
Antibodies, Next-Generation Checkpoint
Immunomodulators
Program: BNT312Presentation Title:
First-in-human phase 1/2 trial to evaluate the safety and initial
clinical activity of DuoBody®-CD40×4-1BB (GEN1042) in patients
with advanced solid tumorsSession Title: Concurrent Rapid
Oral Abstract Presentation Session 206: ClinicalSpeaker:
Melissa L. Johnson, M.D., Lead Investigator, Associate Director,
Lung Cancer Research, Sarah Cannon Cancer Institute, TriStar
Centennial Medical CenterAbstract Number: 493Date &
Time: Saturday, November 13, 2021, 12:45 pm - 1:45 pm
ET Poster Details:
All data presented in poster presentations at
the poster hall will be made available as virtual ePosters
throughout the SITC 36th Virtual Annual Meeting.
mRNA Therapeutics, FixVac
Program: BNT111Poster Title: An
RNA lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity
and promising clinical activity in a Phase I trial in cutaneous
melanoma patients with no evidence of disease at trial
inclusionAbstract Number: 15965Date & Time:
Friday, November 12, 2021, 7:00 am - 8:30 pm ET
Program: BNT112Poster Title: A
first-in-human (FIH) Phase I/IIa clinical trial assessing a
ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens
for immunotherapy of prostate cancer; preliminary analysis of
PRO-MERITAbstract Number: 15941Date & Time:
Friday, November 12, 2021, 7:00 am - 8:30 pm ET
Engineered Cell Therapies, NEO-STIM®
Program: BNT221Poster Title:
BNT221, an autologous neoantigen-specific T-cell product for
adoptive cell therapy of metastatic ovarian cancerAbstract
Number: 201Date & Time: Friday, November 12,
2021, 7:00 am - 8:30 pm ET
Antibodies, Next-Generation Checkpoint
Immunomodulators
Program: BNT311Short Presentation
Title: Peripheral and tumoral immune activity in the expansion
part of the first-in-human DuoBody®-PD-L1×4-1BB (GEN1046)
trialAbstract Number: 516Date & Time: Saturday,
November 13, 2021, 7:00 am - 8:30 pm ET
Program: BNT311Short Presentation
Title: Dose selection for DuoBody®-PD-L1×4-1BB (GEN1046) using
a semimechanisticpharmacokinetics/pharmacodynamics model that
leverages preclinical and clinical dataAbstract Number:
786Date & Time: Saturday, November 13, 2021, 7:00
am - 8:30 pm ET
Small Molecule Immunomodulators, Toll-like
Receptor (TLR) Binding platform
Program: BNT411Short Presentation
Title: Preliminary safety, PK/PD and efficacy results from a
first-in-human phase I/IIa clinical trial of BNT411, a systemic
Toll-like receptor 7 agonist in patients with solid
tumorsAbstract Number: 525Date & Time: Friday,
November 12, 2021, 7:00 am - 8:30 pm ET
About BioNTechBiopharmaceutical New
Technologies is a next generation immunotherapy company pioneering
novel therapies for cancer and other serious diseases. The Company
exploits a wide array of computational discovery and therapeutic
drug platforms for the rapid development of novel
biopharmaceuticals. Its broad portfolio of oncology product
candidates includes individualized and off-the-shelf mRNA-based
therapies, innovative chimeric antigen receptor T cells, bispecific
checkpoint immuno-modulators, targeted cancer antibodies and small
molecules. Based on its deep expertise in mRNA vaccine development
and in-house manufacturing capabilities, BioNTech and its
collaborators are developing multiple mRNA vaccine candidates for a
range of infectious diseases alongside its diverse oncology
pipeline. BioNTech has established a broad set of relationships
with multiple global pharmaceutical collaborators, including
Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the
Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer.
For more information, please visit
www.BioNTech.de
Investor RelationsSylke Maas, Ph.D. VP
Investor Relations & Strategy Tel: +49 (0)6131 9084 1074
E-mail: Investors@biontech.de
Media RelationsJasmina AlatovicDirector
Global External Communications Tel: +49 (0)6131 9084 1513 or +49
(0)151 1978 1385 E-mail: Media@biontech.de
BioNTech (TG:22UA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
BioNTech (TG:22UA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024